Cancer Immunology Research · 2018 · 47 citations · 32 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsT Cell Responses To TumorsAdaptive Antitumor ImmunityAntigen Presenting CellsCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesCd8 Positive T CellsImmune Checkpoint Blockade SynergyPd-l1 BlockadeT-cell Responses To Tumor Antigens
Abstract The protective capability of tumor antigen–specific T cells is regulated by costimulatory and inhibitory signals. Current approaches in cancer immunotherapy seek to restore the function of unresponsive T cells by blocking inhibitory pathways. In contrast, providing exogenous costimulatory signals to T cells also enhances antitumor functionality. By combining these two clinical approaches, we demonstrate the synergy of targeting PD-L1 together with the costimulatory molecule OX40, to enhance antitumor immunity. Concurrently blocking PD-L1 and providing a costimulatory agonist to OX40 increased the presence and functionality of tumor antigen–specific CD8+ T cells with simultaneous enhancement of T-helper type 1 (Th1)-skewed CD4+ T cells. This shift was functionally supported by increased glucose metabolism of antigen-specific CD8+ T cells and the acquisition of granzyme B by regulatory T cells. Together, this mechanism promoted tumor regression of late-stage tumors beyond that achieved by either blockade as monotherapy. These findings indicate that targeting both T-cell intrinsic (OX40) and extrinsic (PD-L1) regulatory molecules increases the bioenergetic potential of T cells, thereby expanding functional and tumor antigen–specific T cells.
32
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih‐Hao Chang, Jing Qiu, David O’Sullivan et al. · Cell · 2015 · 3.2K citations · Full text
Medicine, Cancer Biology, Oncology +16
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chih‐Hao Chang, Jonathan D. Curtis, Leonard B. Maggi et al. · Cell · 2013 · 2.2K citations · Full text
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Enfu Hui, Jeanne Cheung, Jing Zhu et al. · Science · 2017 · 1.7K citations · Full text
Life Sciences, Immunology, Oncology +17